Previous studies suggests FASN expression is positively correlative with PD-L1 level in cisplatin-resistant lung cancer cells and a human T-cell leukemia line 98, 99, and FASN inhibitor orlistat could suppress cell proliferation and downregulate PD-L1 expression 99. Here, FASN is linked to lung carcinoma.